Keytruda (pembrolizumab) plus Inlyta (axitinib) | Friends of Cancer Research

You are here

Keytruda (pembrolizumab) plus Inlyta (axitinib)

Sponsor: 
Merck & Co. Inc. and Pfizer, Inc.
Indication: 
First-line treatment of patients with advanced renal cell carcinoma (RCC)
Category: 
Year: 
2017
Date: 
Dec 10th
FDA Status: 
FDA Approval
Approval Date: 
Apr 19th
Approval Year: 
2018